Windows of opportunity for Ebola virus infection treatment and vaccination
Abstract
Ebola virus (EBOV) infection causes a high death toll, killing a high proportion of EBOV infected patients within 7 days. Comprehensive data on EBOV infection are very fragmented, hampering efforts in developing therapeutics and vaccines against EBOV. Under this circumstance, mathematical models become valuable resources to explore potential controlling strategies. In this paper, we employed experimental data of EBOV-infected nonhuman primates (NHPs) to construct a mathematical framework for determining windows of opportunity for treatment and vaccination. Considering a prophylactic vaccine based on recombinant vesicular stomatitis virus expressing the EBOV glycoprotein (VSV-EBOV), we found that the time window can be subject-specific, but vaccination could be protective if a subject is vaccinated during a period from one week to four months before infection. For the case of a therapeutic vaccine based on monoclonal antibodies (mAbs), a single dose might resolve the invasive EBOV replication even it was administrated as late as four days after infection. Our mathematical models can be used as building blocks for developing therapeutic and vaccine modalities as well as for evaluating public health intervention strategies in outbreaks. Future laboratory experiments will help to validate and refine the estimates of the windows of opportunity proposed here.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 35
- FWCI
- 4.21
- Field percentile
- top 5%
- Organism
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Low-dose VSV-EBOV vaccination provides rapid protection from lethal Ebola virus challenge
Andrea Marzi, Wakako Furuyama, … Heinz Feldmann·bioRxiv·Feb 15, 2026
- Prior vaccination with the rVSV-ZEBOV vaccine does not interfere with but improves the efficacy of postexposure antibody treatment in nonhuman primates exposed to Ebola virus
R. W. Cross, Z. A. Bornholdt, … T. W. Geisbert·bioRxiv·Apr 1, 2020
- Ebola virus glycoprotein domains associated with protective efficacy
B. Bhatia, W. Furuyama, … A. Marzi·bioRxiv·May 22, 2021
- Two-antibody pan-ebolavirus cocktail confers broad therapeutic protection in ferrets and nonhuman primates
Z. A. Bornholdt, A. S. Herbert, … J. M. Dye·bioRxiv·Aug 19, 2018
- Reversion of Ebolavirus Disease from a Single Intramuscular Injection of a pan-Ebolavirus Immunotherapeutic
E. Kuang, R. W. Cross, … Z. A. Bornholdt·bioRxiv·Jan 6, 2022
- Acute malaria dysregulates specialized lymph node macrophages to suppress vaccine-elicited protection against Ebola virus
Jonah M. Elliff, Lindsey Grady, … Wendy J. Maury·mBioPeer-reviewed·Dec 30, 2025